Elastic Compression Stockings and Varicose Veins Recurrence

NCT ID: NCT04231942

Last Updated: 2025-06-13

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 319 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-16
• Study Completion Date: 2027-12-31

Brief Summary

Hypothesis. Regular using of Class 1 below-knee graduated compression stockings (RAL GZ 387 standard) compared to the absence of elastic compression will reduce the risk of clinically significant varicose veins recurrence at 12 months after endovenous thermal ablation of the great saphenous vein and elimination of varicose tributaries.

Detailed Description

The incidence of new varicose veins (VVs) appearance at 3 years after any invasive treatment is about 20%, and the progression rate of chronic venous disease (CVD) at 2 years after the endovenous thermal ablation (ETA) reaches 40%. When comparing open surgery and endovenous laser ablation (EVLA), the frequency of VVs recurrence at 12 months after intervention does not significantly differ and amounts to 10%. A previous study examining the effect of elastic compression on the risk of VVs recurrence after surgery showed a 92% reduction in relative risk. However, it was limited to the low number of followed patients and the absence of the compliance measurement. Thus, there is still no evidence, if long term using of graduated compression stockings (GSV) after modern modalities of VVs treatment (ETA with mini/micro phlebectomy or sclerotherapy) provides any benefits in the reduction of VVs recurrence. Also, there is no information on what regimen for GCS using is effective to reduce the risk of VVs recurrence: continuous use at every day or intermittent using only during specific activities.

Our hypothesis is that regular using of Class 1 below-knee graduated compression stockings (RAL GZ 387 standard) compared to the absence of elastic compression will reduce the risk of clinically significant varicose veins recurrence at 12 months after endovenous thermal ablation of the great saphenous vein and elimination of varicose tributaries.

The aim of the study is to assess the efficacy of regular using of below-knee graduated compression stockings (GCS) of Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) on the risk of varicose veins clinical recurrence after endovenous thermal obliteration of the great saphenous vein and eliminating varicose tributaries in patients without residual varicose veins and / or venous symptoms.

Conditions

Varicose Veins; Chronic Venous Insufficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Group 1 (experimental): continuous using of GCS

At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).

In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;

Group Type: EXPERIMENTAL

Graduated Compression Stocking: continuous using

Intervention Type: DEVICE

Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings

Group 2 (experimental): intermittent using of GCS

At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).

In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;

Group Type: EXPERIMENTAL

Graduated Compression Stocking: intermittent using

Intervention Type: DEVICE

Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings

Group 3 (control): no use of GCS

At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).

The use of GCS will be possible "on-demand" when symptoms or risk factors appear after appropriate coordination with the Investigator

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Graduated Compression Stocking: continuous using

Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings

Intervention Type: DEVICE

Graduated Compression Stocking: intermittent using

Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age over 18 years;
• Varicose veins (VVs) in the system of great saphenous vein (GSV) of one lower limb;
• Performed endovenous thermal ablation (ETA) of the GSV trunk - endovenous laser ablation (EVLA) or radiofrequency ablation (RFA) - and elimination of varicose tributaries by mini (micro) phlebectomy or sclerotherapy during the 30-45 days before enrollment;
• The technical success of the performed ETA, the absence of reflux in the GSV trunk and the absence of residual VVs;
• Lack of signs of chronic venous disease (CVD): clinical class of C0-1 according to the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification;
• Lack of vein-specific symptoms - the intensity of any validated vein-specific symptom is less than 30% according to the numeric rating scale (NRS);
• Signed informed consent.

Exclusion Criteria

• Bilateral VVs;
• Primary reflux outside the GSV trunk (including combined);
• History of deep or superficial veins thrombosis;
• Verified deep vein reflux;
• Verified non-thrombotic or post-thrombotic venous obstruction;
• Verified pelvic venous insufficiency;
• Persistence of superficial reflux after ETA;
• A tendency for recanalization of previously obliterated veins;
• Persistence of residual VVs - clinical class of C2 by CEAP;
• Persistence of signs of CVD - clinical class of C3 and higher by CEAP;
• Persistence of one or more vein-specific symptom with an intensity of 30% and higher by NRS;
• The need for long-term use of elastic compression;
• Contraindications or restrictions for the long-term use of GCS;
• The need for long-term use of vein-active drugs (more than 1 month);
• Refusal to participate in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pirogov Russian National Research Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Leonid Laberko, PhD

Role: STUDY_CHAIR

Pirogov RNRMU

Leonid Laberko, PhD

Role: PRINCIPAL_INVESTIGATOR

Pirogov RNRMU

Locations

Moscow Clinical Hospital name by A.K. Yeramishantsev

Moscow, , Russia

Moscow Clinical Hospital no.24

Moscow, , Russia

Moscow private medical clinic "MedSwiss"

Moscow, , Russia

Countries

Russia

Other Identifiers

ECOS-VVR

Identifier Type: -

Identifier Source: org_study_id